Comparison of the mucosal adjuvant Endocine™ with two well-known adjuvants: cholera toxin and alum
2015 (English)In: Jacobs Journal of Vaccine and Vaccination, Vol. 1, no 1, 006Article in journal (Refereed) Published
To enable efficient mucosal vaccination with split or subunit antigens, an adjuvant is often needed. To date, no mucosal adjuvants are approved for human use, however, there are a variety of mucosal adjuvants in development, including the liposome-based adjuvant Endocine™. The aim of this study was to evaluate split influenza antigens together with Endocine™ and in order to assess the potency of Endocine™, the induction of humoral immune responses were compared to those following influenza vaccination with cholera toxin (CT) or aluminum salt (alum). We show that Endocine™ significantly enhances influenza-specific immune responses in intranasally immunized mice compared to nonadjuvanted vaccine. Furthermore, vaccines adjuvanted with Endocine™ evoked comparable serum IgG and virus neutralizing (VN) antibody titers as nasal vaccines adjuvanted with CT. Compared to parenteral vaccination with alum, Endocine™ triggered significantly higher mucosal and serum IgA titers, and similar VN titers. Taken together, these results support further development of Endocine™ as a mucosal adjuvant and as part of a nasal influenza vaccine candidate.
Place, publisher, year, edition, pages
Jacobs Publishers , 2015. Vol. 1, no 1, 006
Mucosal adjuvant; nasal immunization; vaccine; Endocine; influenza; neutralizing antibodies
Clinical Laboratory Medicine Cell and Molecular Biology
IdentifiersURN: urn:nbn:se:liu:diva-117979OAI: oai:DiVA.org:liu-117979DiVA: diva2:812606